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ABSTRACT 
Purpose: In patients with advanced oesophageal carcinoma palliation of dysphagia is 
important to maintaining a reasonable quality of life. The primary aim of this study was to 
determine the dysphagia progression-free survival (DPFS) in patients with advanced 
oesophageal carcinoma treated with palliative radiotherapy (RT). 
Methods:  The medical records of all patients with oesophageal carcinoma presenting to 
Groote Schuur Hospital, Cape Town between January 2015-December 2016 were reviewed 
and patients who were not candidates for curative treatment and received palliative RT were 
selected. For these patients, the dysphagia score (DS) was recorded prior to RT, 6 weeks after 
RT and at each follow-up visit. The DPFS was calculated as the time from completion of RT 
to worsening in DS by ≥1 point or until death. Other outcomes measured were objective 
change in DS and survival post RT.  
Results: The study population comprised 84 patients. Squamous cell cancer was the primary 
histological subtype (93%). The median duration of DPFS after RT was 73 days, with 
approximately two-thirds of patients remaining able to swallow at least liquids and soft diet 
until death. The difference in median duration of DPFS was not statistically significant in 
stented versus non-stented patients (54 days vs 83 days; p =0.224). The mean change in DS 
was 0.45 ± 0.89 points following RT and the post RT survival was significantly shorter in 
patients with stent insertion (81 days vs 123 days; p=0.042). 
Conclusion: Palliative RT can be used successfully to prolong DPFS in patients with locally 
advanced and metastatic squamous cell cancer of the oesophagus. 
Key Words: Oesophageal cancer, locally advanced, dysphagia score, palliative radiotherapy. 







Worldwide, nearly 456,000 new cases of oesophageal cancer were estimated to have been 
diagnosed in 2012, with incidence rates varying across the world (1,2). It was described as 
the 6th leading cause of cancer related death in men and 9th leading cause of cancer related 
death in women in 2012 (2). Oesophageal cancer was the 8th most common cancer diagnosed 
in South Africa in 2013 (3). Approximately 70% of cases in England, Scotland and Northern 
Ireland in 2014 were diagnosed at a late stage (1). Although definitive data is lacking for 
South Africa, the majority of new cases follow a similar trend with a high percentage of 
patients presenting with locally advanced or metastatic disease. The average survival in these 
patients range from 4-6 months and palliation of their symptoms, specifically dysphagia is 
crucial to maintaining an acceptable quality of life. 
Purpose of the Study 
The primary aim: 
• To determine the mean dysphagia progression-free survival after radiation therapy in 
patients with locally advanced or metastatic oesophageal cancer. 
Primary research hypothesis:  
• The mean dysphagia progression-free survival after radiation therapy in patients with 
locally advanced or metastatic oesophageal cancer is within the range of 3-6 months. 
The secondary aims: 
• To determine if patients with oesophageal stenting had a longer dysphagia progression-
free survival compared to those without oesophageal stenting. 
• To determine if there is an overall quantitative objective improvement in dysphagia grade 
of patients with locally advanced and metastatic oesophageal cancer receiving palliative 
radiation therapy. 
• To determine the overall survival in patients who received palliative radiation therapy. 
Secondary research hypotheses: 
• Patients who had both oesophageal stenting and palliative radiation therapy had a longer 
dysphagia progression-free survival when compared to those who received only palliative 
radiation therapy without oesophageal stenting. 
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• Radiation therapy increases the mean dysphagia progression-free survival (in months) in 
patients with locally advanced or metastatic oesophageal cancer. 
• Palliative radiation therapy increases the overall survival in patients with metastatic and 
locally advanced oesophageal cancer. 
Background 
Palliation of dysphagia in patients with locally advanced and metastatic oesophageal cancer is 
still an area of contention as there currently are no consensus guidelines for the optimal 
management. Various studies have been done comparing the benefit of radiotherapy (both 
external beam radiation therapy and brachytherapy) to endo-luminal stenting while evaluating 
variables such as time to treatment, time to improvement of dysphagia score and efficacy of 
treatment for long term control of symptoms. Retrospective studies demonstrated that 
endoscopic stenting provided earlier and more rapid relief of symptoms, however, was 
associated with recurrent dysphagia in the long term compared to radiotherapy. These studies 
suggested the optimal management for palliation of dysphagia in these patients to be a 
combination of endo-luminal stenting and radiation therapy (4,5). Although previous data 
suggests long term relief of dysphagia in patients with locally advanced and metastatic 
oesophageal cancer, limited data is available to suggest the duration of this response. One 
retrospective study conducted in Germany analysing 139 patients with advanced/incurable 
oesophageal cancer treated with palliative radiation therapy between 1994 to 2004 reported 
subjective symptom relief in 72 % of patients with median response duration of 5 months (6). 
Our study is aimed primarily at examining the median overall duration of response to 
radiation therapy in this subgroup of patients in our clinical setting. We also aim to identify 
any contributing factors (such as dose and fractionation, endo-luminal stenting) that may 
affect the overall response to palliative radiation therapy. 
Methodology 
This is a retrospective, observational study. The medical records of all patients presenting to a 
public hospital in South Africa over the period January 2015-December 2016 will be 
reviewed. The patients presenting with dysphagia secondary to locally advanced or metastatic 
oesophageal cancer who were treated with palliative radiation therapy will be selected for 
further data collection and analysis. 
Formal sample size calculations will not be performed. The number of subjects was chosen 
based on feasibility of data collection and is considered sufficient to meet the study 
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objectives. All patients who meet the inclusion criteria and determined to have a dysphagia 
grade of 1-4 at the time of presentation or during follow-up using the Knyrim et al (2013) 
dysphagia score grading system would have been offered oesophageal stenting +/- palliative 
radiation therapy. They would be reassessed 6 weeks post radiation therapy and then seen 
routinely every three months or earlier if worsening in dysphagia. The medical records of 
these patients will be reviewed for objective worsening of dysphagia grade at these visits. 
The dysphagia progression-free survival will be taken as the time from the completion of 
radiation therapy to worsening in dysphagia grade by at least one point. Patients who have 
died without returning to follow-up with complaint of increasing dysphagia are assumed to 
have dysphagia progression-free survival from time of radiation therapy until death. This 
information will be used to determine the primary and secondary endpoints of the study. 
Characteristics of study population 
The study population includes all new patients presenting to the gastro-oesophageal oncology 
clinic at Groote Schuur Hospital, Cape Town, South Africa (estimated to be approximately 
150 patients) with metastatic or locally advanced oesophageal cancer. Of these, the patients 
to be selected for further analysis must fulfil the following criteria (estimated to be 80-100 
patients): 
Inclusion criteria:  
• At least 18 years of age. 
• Presentation between January 2015 to December 2016 with dysphagia either at initial 
visit or during follow-up. 
• Stage I to III oesophageal cancer who are not potentially resectable (not 
physiologically fit, <5cm from crico-pharyngeus, gastro-oesophageal junction 
involvement, tumours involving the heart, great vessels, trachea or adjacent organs 
including the liver, pancreas, lung and spleen or multi-station, bulky 
lymphadenopathy) or metastatic oesophageal cancer. 
• Received palliative radiation therapy for symptom control. 
• Performance Status (ECOG): 0-4 
• Dysphagia score of 1-4 (at presentation or during follow-up) 
• With or without oesophageal stent insertion 
Exclusion criteria: 
• Less than 18 years of age. 
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• Stage I to III oesophageal cancer who are potentially resectable (physiologically fit, 
>5cm from crico-pharyngeus, tumours not involving the heart, great vessels, trachea 
or adjacent organs including the liver, pancreas, lung and spleen or no multi-station, 
bulky lymphadenopathy) and hence are amenable to radical treatment. 
• Patients qualifying for definitive chemo-radiation therapy treatment (physiologically 
fit and non-metastatic). 
• Dysphagia score 0 (at presentation or during follow-up) 
• Patients who received palliative chemotherapy  
Recruitment and Enrollment 
The patients to be recruited will be determined by reviewing the logs of patients who 
presented to the clinic and will be performed by the primary investigator. Since the study is a 
retrospective observational study and the necessary information will be collected by 
reviewing the medical records in the target population there will be no potential for 
therapeutic misconception. 
Research Procedures and Data Collection Methods 
 A data collection form will be designed using the REDCap software which would include 
the basic patient demographics and information regarding diagnosis and treatment details. 
The selected patients’ hospital medical records will be used to fill out the required 
information for the study. There will be no direct interaction with the patient. 
Data Analysis 
The data collected will be stored in the REDCap database and the interface will be used to 
process the data and analyse the variables relevant to the study. The data collected using 
REDCap software is only accessible to the primary investigator and the student investigator. 
No identifying information would be collected during data synthesis. 
All collected data would be displayed in tables and charts. SPSS software would be used to 
perform statistical analyses. Dysphagia progression-free survival was defined as the time to 
worsening of dysphagia by at least one grade. 
The raw data collected will be presented in the form of tables and charts. The data will be 
processed using Kaplan-Meier analysis to determine the dysphagia progression-free survival.  
Description of Risks and Benefits 
Potential risks and discomforts 
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This is an observational retrospective study, therefore, the associated research risk is low 
because the research does not affect the patient’s management or outcome in any way and the 
necessary data can be collected from patients’ medical records of routine scheduled clinic 
visits and national death records. Efforts will be made to ensure patient confidentiality as 
described above. 
Potential benefits 
There are no potential benefits to participants in the research as there will be no direct contact 
with these patients and the study does not affect their management in any way. There is a 
potential for benefit to the community and health services as there is currently limited data 
for the outcomes being analysed in our local and regional setting. Therefore, the data can 
potentially be used to improve patient care and outcomes in the future. 
Informed Consent Process 
Consent will not be obtained because the study is retrospective and does not directly involve 
the patients 
Privacy and Confidentiality 
The data will be collected using RedCap software and will only be accessible to the primary 
investigator and the student investigator. The data collection form will include the patients’ 
hospital registration number to allow for easier data collection however this information will 
not be displayed when the data is processed and tabulated and hence will only be visible to 
the investigators. All data will be kept confidential to protect the patient’s privacy. 
Reimbursement for Participation 
There will be no reimbursement for participation as the study does not involve direct 
interaction with the patient as all necessary information is collected from the patients’ 
medical records. 
What Happens at the End of a Study? 
The data will be used to determine the primary and secondary outcomes. This information 
will then be used to determine further patient management in subgroup of patients examined 
in the study population. The conclusions of the study will be submitted for publication in a 
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This literature review seeks to examine the relevant existing information regarding the 
management of dysphagia in patients with locally advanced and metastatic oesophageal 
cancer. It will examine the methods used in treatment and the outcomes measured in order to 
assess and determine the quality of response. Appropriate management of dysphagia in 
patients with oesophageal cancer is crucial to maintaining a reasonable quality of life.  
For this literature review, local, regional and global cancer statistics were reviewed for 
patterns associated with incidence and epidemiology. An online search was conducted using 
PubMed, EMBASE and MEDLINE for articles related to the management of dysphagia in 
patients with locally advanced and metastatic oesophageal cancer published in medical 
journals or in evidence-based databases such as Cochrane database and National Library of 
Health (UK).  
Several studies have been conducted regarding the palliation of dysphagia in patients with 
oesophageal cancer. Interventions such as endoluminal stenting, external beam radiation 
therapy, brachytherapy, laser ablation, surgical bypass have been described and compared. 
However, there is still no consensus regarding the most effective approach to the 
management of these patients. 
This highlights the need for further research in objectively assessing outcomes following the 
treatment of patients with locally advanced and metastatic oesophageal cancer. 
INTRODUCTION 
According to international statistics, in 2012, the estimated number of new oesophageal 
cancer cases was approximately 456,000, with incidence rates varying across the world(1, 2). 
The highest incidence rates are in Asia, and in East and South Africa while the lowest rates 
are found in Western Africa and in parts of Europe and South America in women. In 2013 
oesophageal cancer was the 9th most common cancer diagnosed worldwide(3), ranked as the 
8th most common cancer diagnosed in developing countries including South Africa(4) and the 
20th most common cancer diagnosed in developed countries.  
 
In 2012, approximately 400,200 people died from oesophageal cancer, with developing 
countries accounting for more than 80% of these deaths. In 2013, oesophageal cancer was 
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ranked 6th in cancer related mortality worldwide, ranking 5th in developing countries and 11th 
in developed countries(3).   
The prevalence of oesophageal cancer is approximately three to four times higher among men 
than women. In 2013, it was the 6th leading cause of cancer related death in men and 9th 
leading cause of cancer related death in women in 2012 worldwide(2).  
 
The incidence of oesophageal cancer also varies with age; with minimal occurrences in 
people less than 40 years old and increasing thereafter to be the highest in the elderly aged 
70-80 years(5). The two main histological subtypes of oesophageal cancer are squamous cell 
carcinoma and adenocarcinoma. These two subtypes have distinct aetiologies and the disease 
course and response to treatment are usually variable(6). Squamous cell carcinoma (SCC) of 
the oesophagus is associated mainly with dietary factors, cigarette smoking and alcohol and 
has a higher incidence in poverty-stricken populations. However, oesophageal 
adenocarcinoma is a disease of prosperity, with the highest incidence occurring in high 
income Western countries and the most significant risk factors being gastro-oesophageal 
reflux and obesity(2, 7, 8). South-Eastern and Central Asia comprises 79% of the total SCC 
cases globally, while the highest burden of adenocarcinoma (AC) is found in Northern and 
Western Europe, Northern America and Oceania(7). 
 
Due to the expansile characteristics of the oesophagus, symptoms related to obstructing or 
stricturing lesions tend to manifest only in advanced stages of disease. International data 
reports that in Europe and North America, many patients with oesophageal cancer present 
with locally advanced or metastatic disease and are not candidates for curative treatment; 
approximately 70% of cases in Scotland and Northern Ireland in 2014 were diagnosed at a 
late stage(1) and in the United Kingdom 70-80% of patients were diagnosed with either lymph 
nodes or distant metastases, and 37-42% had distant metastases at diagnosis(9). Although 
definitive data is lacking for South Africa, most new cases follow a similar trend with a high 
percentage of patients presenting with locally advanced or metastatic disease. One 
retrospective study conducted by Dandara et al (2016) examining all patients presenting with 
oesophageal cancer over a 30-year period reported that 76% of patients presented with 
advanced disease and poor clinical condition requiring palliative care(10). In patients 
presenting with locally advanced and metastatic oesophageal cancer, the outcome is very 




The most common symptoms in patients with oesophageal cancer are dysphagia, weight loss, 
odynophagia, chest pain, gastro-oesophageal reflux and regurgitation(12). Dysphagia is 
defined as the inability to pass liquids or food voluntarily from the mouth to the stomach and 
is documented as the most common presenting symptom in patients with oesophageal cancer 
in several studies, occurring in 70-80% of patients at presentation(13, 14). One large study 
conducted by the American college of Surgeons (2000) reported dysphagia in 74% of the 
5044 patients enrolled(15). Dysphagia has a significant impact on quality of life and is often 
associated with weight loss and poor nutritional status. These factors are contributory to the 
poor clinical condition that precludes many patients from receiving curative treatment(16-18). 
 
Palliation of dysphagia in patients with locally advanced and metastatic oesophageal cancer is 
an area of contention as currently there are no consensus guidelines for the optimal 
management. It also presents a significant problem in developing countries because of the 
high volume of patients diagnosed at advanced stage disease coupled with the added problem 
of access to resources(19). Hence, it is particularly important in these regions to establish a 
cost effective and efficacious method of palliation of dysphagia in this population of patients. 
 
The purpose of this literature review is to examine the existing data regarding palliation of 
dysphagia patients with locally advanced and metastatic oesophageal cancer and the 
outcomes following treatment. Focus will be on the use of radiation therapy in this clinical 
scenario and the outcomes following treatment with respect to the magnitude and duration of 
response. The outcomes of other interventions used for palliation of dysphagia will also be 
analyzed and compared to radiation therapy, with an aim of determining the efficacy 
radiation therapy for palliation of malignant dysphagia which can be adapted to our clinical 
environment as a developing country. 
 
METHODS 
For this literature review, local, regional and global cancer statistics were reviewed for 
patterns associated with incidence and epidemiology. An online search was conducted using 
PubMed, EMBASE and MEDLINE (1980 to 2015) for relevant articles and abstracts 
published in medical journals or in evidence-based databases such as Cochrane database and 
National Library of Health (UK). A combination of subject headings and text words relating 
to the management of dysphagia in patients with locally advanced and metastatic oesophageal 
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cancer was used. This search was repeated in March 2020 prior to submission of the 
manuscript.  
The inclusion criteria were articles relating to any intervention used for palliation of 
dysphagia in patients with incurable oesophageal cancer. Articles related to intervention in 
curable patients or patients without dysphagia were excluded. Thirty-seven journal articles 
were included in this literature review. 
DISCUSSION: 
There are several options for the palliation of malignant dysphagia, which include stent 
placement, dilatation, external beam radiotherapy, brachytherapy, chemotherapy, laser 
treatment, photodynamic therapy or ablation; however, the optimal intervention strategy has 
not been established(20, 21). Various studies have been conducted comparing these 
interventions using various outcomes related to symptom control to determine the efficacy of 
treatment. One large meta-analysis conducted by Dai et al in 2014 consisted of 53 studies and 
included 3684 patients aimed to determine the optimal intervention for the palliation of 
dysphagia in patients with incurable oesophageal cancer. The outcomes assessed were 
improvement in dysphagia grade, overall survival, time interval to improvement of 
dysphagia, incidence and time interval to recurrence of dysphagia and need for further 
interventions, adverse effects and mortality of each intervention and quality of life. The 
results of the meta-analysis showed “no obvious superiority of any one intervention in 
palliating dysphagia but established self-expanding metal stent insertion as a safe, effective 
and rapid treatment in dysphagia palliation compared to other modalities”. It was also 
reported “due to the high incidence of delayed complications and recurrent dysphagia, rigid 
plastic tube insertion, chemotherapy alone, and combination chemoradiotherapy and bypass 
surgery were not recommended for palliation of dysphagia”. The investigators suggest a role 
for multimodality treatment to improve outcomes(20). 
Other studies examining the role of various modalities in palliation of malignant dysphagia 
support the conclusion of Dai et al and the most pertinent ones will be discussed individually 
in the text. The results of several large series regarding palliative bypass surgery report a 
median survival of less than 6 months while the mortality exceeds 20%. Hence, less invasive 
methods of palliation of dysphagia are preferable to bypass surgical procedures(22).  
Brachytherapy has been studied in the palliative setting both as monotherapy and as part of 
multimodality treatment approach. A prospective study conducted in Netherlands by Homs et 
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al (2004) between 1999-2002 randomly assigned 209 patients with dysphagia secondary to 
inoperable carcinoma of the oesophagus or oesophagogastric junction to stent placement or 
single dose brachytherapy (12Gy). The primary outcome was relief of dysphagia during 
follow-up and secondary outcomes were complications, treatment for persistent or recurrent 
dysphagia, health-related quality of life, and costs. The results showed more rapid 
improvement in dysphagia score after stent placement than after brachytherapy; however, the 
improvement between both modalities was equivalent at the peak of response. At 30 days 
after intervention, the dysphagia score had improved by at least one grade in 73% of patients 
who received brachytherapy and 76% who had stent placement. Subsequently, the dysphagia 
grade declined more rapidly in the patients who had stent insertions than those who had 
brachytherapy thus demonstrating a more durable response following brachytherapy. 
Additionally, patients receiving brachytherapy had better health related quality of life scores 
on several functional scales and lower complication rates compared to patients with stent 
insertion (21% versus 33%). There was no significant difference between persistent or 
recurrent dysphagia, overall survival or costs between both groups. Thus, the investigators 
recommended single-dose brachytherapy preferentially to stent placement as the initial 
treatment for patients with dysphagia due to locally advanced cancer of the oesophagus or 
oesophagogastric junction. They suggested stent placement only for patients with a short life-
expectancy and severe dysphagia requiring rapid symptom control and also in cases of 
persistent or tumour regrowth after brachytherapy(23). These conclusions have been supported 
in several other studies evaluating the role of brachytherapy in palliation of dysphagia(24-28). 
Further to this, a prospective randomized trial of 232 patients conducted in South Africa by 
Sur et al (2002) examined two fractionated high-dose-rate (HDR) brachytherapy regimens 
(18 Gy in 3 fractions on alternate days versus 16 Gy in 2 fractions on alternate days to 
determine which gives the best results in terms of palliation and survival in advanced 
esophageal cancer. The dysphagia-free survival (7.8 months vs 6.3 months) and overall 
survival (9.1months versus 6.9 months) favoured patients receiving 18 Gy in 3 fractions. 
Thus, the authors reported superiority of fractionated HDR brachytherapy as a single 
modality therapy in palliation of dysphagia in advanced oesophageal cancer when compared 
to the results documented in any previous study(29). Due to the lack of necessary expertise and 
technology, the use of brachytherapy is not always widely applicable especially in developing 
countries, hence the use of external beam therapy may be an alternative intervention where 
resources are available. 
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One retrospective study of 45 patients conducted by Rueth et al (2012) in Minnesota, USA 
examined the role of oesophageal stent insertion with or without radiation therapy in the 
management of malignant dysphagia. In this study, 68.9% of patients reported subjective 
improvement of dysphagia immediately after stent insertion. The median overall survival was 
38 days following oesophageal stent insertion only, however patients who received radiation 
therapy following stent placement had a longer median survival (98 days). There was no 
difference in the 30-day mortality or complication rate in patients with the addition of 
radiation therapy to stent insertion. From this study, it was concluded that endoscopic stent 
insertion is a quick and effective method to relieve dysphagia in patients with a short life 
expectancy. However, radiation therapy and stent insertion as part of multimodality 
treatment, provides a superior means of palliation of malignant dysphagia in the long term 
and hence is beneficial in patients with a life expectancy >3 months(30).  
 
Another prospective study from India by Javed et al (2010) showed similar results; 84 
patients with inoperable oesophageal cancer were randomized to receive oesophageal stenting 
alone or a combination of oesophageal stenting and external beam radiotherapy (EBRT). 
Dysphagia scores improved significantly in both groups following stent insertion. However, 
the duration of response (7 vs. 3 months, p=0.002) was more sustained and overall median 
survival was significantly higher (180 vs. 120 days, p=0.009) in patients receiving stenting 
plus EBRT versus stenting alone with similar complication rates between both groups. 
Interestingly, there was significant improvement in all quality of life parameters after stent 
insertion, however, there was significant decline immediately after radiotherapy. 
Nonetheless, these results support previous data that EBRT following stent insertion can 
effectively prolong the duration of dysphagia control and improve overall survival in patients 
with inoperable oesophageal cancer(31). There is limited data regarding the quality of life 
following interventions for dysphagia and this study highlighted an important finding not 
previously reported; that despite the improved symptom control, there was a deterioration in 
health-related quality of life. 
 
Existing data reports that although endo-luminal stenting provided earlier and more rapid 
relief of symptoms, it was associated with recurrent dysphagia in the long term while 
radiation therapy provided more durable response and was associated with a lower 
complication rate. These studies suggested the optimal management for palliation of 
dysphagia in these patients is a combination of endo-luminal stenting and radiation therapy or 
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brachytherapy(32, 33). The addition of chemotherapy to radiation therapy shows a modest but 
not significant benefit over radiation therapy only(34) and considering the increased toxicity 
associated with concurrent chemo-radiation therapy may not be considered a viable option in 
the palliative setting. 
 
Although the available data suggests effective relief of dysphagia in patients with locally 
advanced and metastatic oesophageal cancer treated with palliative radiation therapy(11), 
limited data is available to suggest the duration of this response and optimal fractionation 
regimen. A retrospective study of the use of radiation therapy in palliation of dysphagia 
conducted in the Netherlands by Caspers et al (1988) compared EBRT regimens (>50Gy 
versus <50Gy). There was an improvement in dysphagia score in 70.5% of patients with a 
median dysphagia-free interval of 3.7 months in patients with severe dysphagia and 16.0 
months in patients with mild to moderate dysphagia, while overall survival was 6.4 months 
and 8.7 months respectively. The results showed better outcomes in patients receiving more 
than 50 Gy and in patients with less dysphagia at baseline(35). 
 
One retrospective study conducted in Germany by Welsch et al (2016) analysed 139 patients 
with advanced/incurable oesophageal cancer treated with palliative radiation therapy between 
1994 and 2014. The radiation was delivered as external beam radiation therapy (30-40 Gy in 
2.5-3Gy per fraction) with or without endoluminal high dose rate brachytherapy. The 
parameters used to assess response were 6-month dysphagia-free survival, improvement in 
swallowing function, complication rate, and overall survival. The results showed subjective 
symptom relief in 72% of patients with median response duration of 5 months, 6-month 
dysphagia-free survival was 73+/- 4% and the median overall survival was 10 months. These 
results favoured patients receiving external beam radiation therapy (EBRT) with or without 
brachytherapy and demonstrated its superiority to brachytherapy as monotherapy(36). The 
study by Sur et al (2002) that was earlier described in the text had suggested that fractionated 
HDR brachytherapy yielded superior results in terms of dysphagia-free survival than any 
other intervention up to that time(29). It is important to note that the HDR brachytherapy 
fractionation regimens used in treatment and that the endpoints to establish response were 
different between these two studies and hence a conclusion cannot be drawn regarding the 
superiority of either intervention. 
Dysphagia, in addition to the impact on nutritional status and performance status, contributes 
significantly to the poor quality of life in patients with oesophageal cancer(37). Hence, in 
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addition to assessing the response in terms of dysphagia improvement and survival outcomes, 
it is also important to assess the impact on quality of life in these patients following 
intervention(17). Several studies have examined the impact of various interventions on health-
related quality of life yielding positive results with palliative radiation therapy, endoluminal 
brachytherapy and stenting all leading to significant improvements in quality of life(16, 18, 23, 38, 
39).  However, the magnitude of this impact has not been directly compared hence it is 
difficult to determine which is superior in this regard. 
 
CONCLUSION 
There is abundant data available regarding the palliation of malignant dysphagia. Several 
interventions have been studied, however there is still no consensus regarding the optimal 
management. Surgical bypass is associated with high morbidity and mortality and hence less 
invasive methods of palliation are more acceptable. Concurrent chemo-radiation therapy 
marginally increases the benefit over radiation therapy only and is associated with increased 
toxicity and hence is also not recommended in palliation. Oesophageal stent insertion has 
been associated with rapid relief of symptoms but is associated with a higher rate of 
complications than other interventions and frequent need for repeat intervention. The duration 
of response as monotherapy is limited. External beam radiation therapy and brachytherapy 
have both proven to be effective in relief of dysphagia as monotherapy and in combination or 
as an adjuvant to stent insertion. The outcomes following multimodality approach are 
superior to any single intervention and should be tailored to the patient on an individual basis, 
also taking life expectancy and baseline dysphagia grade into consideration. The optimal dose 
and fractionation of external beam radiation therapy and brachytherapy required for effective 
palliation has not been established. Though the response following radiation therapy has been 
documented in terms of proportion of patients experiencing symptom relief and overall 
survival, the duration of response to radiation therapy until worsening of dysphagia is 
unknown. Although there are several studies reporting improvements in quality of life 
following stent insertion, radiation therapy and brachytherapy, these modalities have not been 
compared directly in this regard. 
Hence further research needs to be done comparing health related quality of life scores, 
duration of palliation of dysphagia and absolute improvement in dysphagia grade following 
various interventions as outcomes in assessment of efficacy of palliation of dysphagia. A 
prospective study comparing HDR brachytherapy to EBRT and brachytherapy, which have 
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both been suggested to be the most efficacious methods of palliation in independent studies, 
may also be useful. 
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ABSTRACT 
Purpose: In patients with advanced oesophageal carcinoma palliation of dysphagia is 
important to maintaining a reasonable quality of life. The primary aim of this study was to 
determine the dysphagia progression-free survival (DPFS) in patients with advanced 
oesophageal carcinoma treated with palliative radiotherapy (RT). 
Methods:  The medical records of all patients with oesophageal carcinoma presenting to 
Groote Schuur Hospital, Cape Town between January 2015-December 2016 were reviewed 
and patients who were not candidates for curative treatment and received palliative RT were 
selected. For these patients, the dysphagia score (DS) was recorded prior to RT, 6 weeks after 
RT and at each follow-up visit. The DPFS was calculated as the time from completion of RT 
to worsening in DS by ≥1 point or until death. Other outcomes measured were objective 
change in DS and survival post RT.  
Results: The study population comprised 84 patients. Squamous cell cancer was the primary 
histological subtype (93%). The median duration of DPFS after RT was 73 days, with 
approximately two-thirds of patients remaining able to swallow at least liquids and soft diet 
until death. The difference in median duration of DPFS was not statistically significant in 
stented versus non-stented patients (54 days vs 83 days; p =0.224). The mean change in DS 
was 0.45 ± 0.89 points following RT and the post RT survival was significantly shorter in 
patients with stent insertion (81 days vs 123 days; p=0.042). 
Conclusion: Palliative RT can be used successfully to prolong DPFS in patients with locally 
advanced and metastatic squamous cell cancer of the oesophagus. 
Key Words: Oesophageal cancer, locally advanced, dysphagia score, palliative radiotherapy. 










Worldwide, an estimated 456,000 new cases of oesophageal cancer were diagnosed in 2012, 
with varying incidence rates globally(1, 2). The prevalence of oesophageal cancer is 
approximately three to four times higher among men than women and oesophageal cancer 
was the 6th and 9th leading cause of cancer related death in men and women respectively in 
2012(2). In 2013, oesophageal cancer was the 8th most common cancer diagnosed in South 
Africa(3). Approximately 70% of cases in England, Scotland and Northern Ireland in 2014 
were diagnosed at a late stage (1). Although definitive data is lacking for South Africa, most 
new cases follow a similar trend with a high percentage of patients presenting with locally 
advanced or metastatic disease. One retrospective study conducted in South Africa by 
Dandara et al (2016) examining all patients presenting with oesophageal cancer over a 30-
year period reported that 76% of patients presented with advanced disease and poor clinical 
condition requiring palliative care (4). In these patients receiving palliative care, the average 
survival was approximately 4-6 months(4, 5).  
Dysphagia is documented as the most common presenting symptom prompting patients with 
oesophageal cancer to seek medical care and has a substantial impact on quality of life which 
becomes more significant in advanced disease(6, 7). One large study conducted by the 
American college of Surgeons (2000) reported dysphagia in 74% of the 5044 patients 
enrolled(8). Palliation of this symptom is crucial to maintaining an acceptable quality of life in 
these patients(9-11).  
There are currently no consensus guidelines for the optimal management of dysphagia in 
patients with locally advanced and metastatic oesophageal cancer. Options for palliation 
include stent placement, dilatation, external beam radiotherapy, brachytherapy, 
chemotherapy, laser treatment, photodynamic therapy or ablation(12, 13). Various studies have 
been done comparing the benefit of radiotherapy, both external beam radiotherapy (EBRT) 
and brachytherapy to endoscopic stenting while evaluating various endpoints to determine 
efficacy of treatment. Retrospective studies demonstrated that endo-luminal stenting provided 
earlier and more rapid relief of symptoms, however was associated with recurrent dysphagia 
in the long term(11) , while RT provides more durable response(14). These studies suggested the 
optimal management for palliation of dysphagia in these patients is a combination of endo-
luminal stenting and RT or brachytherapy(13-16). Palliative chemoradiation shows a modest but 
not significant benefit over RT alone(17) and considering the increased toxicity associated 
with concurrent chemoradiation, it is not considered a viable option in palliation. Although 
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previous data suggests effective relief of dysphagia in patients with locally advanced and 
metastatic oesophageal cancer treated with palliative RT(5), limited data is available to 
suggest the duration of this response. One retrospective study of the use of RT in palliation of 
dysphagia conducted in the Netherlands by Caspers et al (1988) reports improvement in 
dysphagia score in 70.5% of patients with a median dysphagia-free interval of 3.7months (18). 
Another retrospective study conducted in Germany by Welsch et al (2016) analyzing 139 
patients with advanced/incurable oesophageal cancer treated  between 1994 to 2004 , with  
either EBRT, brachytherapy or EBRT and brachytherapy combined reported subjective 
symptom relief in 72% of patients with median response duration of 5 months(19). Our study 
was aimed primarily at examining the overall duration of response to RT in our clinical 




Study aims and objectives: 
The aim of this study was to assess the benefit of palliative radiotherapy in the management of 
patients with locally advanced and metastatic oesophageal cancer at a single institution. 
 
The primary objective was to determine the median dysphagia progression-free survival 
(DPFS) after radiation therapy (RT) in patients with locally advanced or metastatic 
oesophageal cancer. The secondary objectives were to compare the duration of DPFS in 
patients with and without oesophageal stenting, to determine the overall quantitative objective 
improvement in dysphagia score (DS) after receiving palliative RT in patients with advanced 
oesophageal cancer and to determine the median overall survival (OS) and post RT survival of 
patients following palliative RT. 
 
Study population: 
The records of all new patients who presented with oesophageal cancer to the gastro-
oesophageal oncology clinic at Groote Schuur Hospital, Cape Town between the period 
January 2015 and December 2016 were reviewed. Only patients with stage I to III 
oesophageal cancer who were not candidates for potentially curative treatment (i.e. not 
physiologically fit, tumours involving adjacent organs or multi-station and bulky 
lymphadenopathy) or with Stage IV disease were selected. Further inclusion criteria were 
patients determined to have a DS 1-4 at initial visit or during follow-up using the Knyrim et 
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al (1993)(20) dysphagia grading system (see Appendix 1) and were treated with palliative 
radiation. Patients who were less than 18 years of age, had received chemotherapy for 
carcinoma of the oesophagus, had percutaneous endoscopic gastrostomy insertion, or patients 
with trachea-oesophageal fistulae were excluded from the study. 
 
Scientific Design: 
This was a retrospective, observational study. The patients meeting the inclusion criteria were 
selected for further data collection and analysis.  
Treatment 
All patients were reviewed in the gastro-oesophageal multidisciplinary team meeting for a 
treatment decision. Patients were selected for palliative treatment based on characteristics at 
presentation such as poor Eastern Cooperative Oncology Group performance status (PS 
(ECOG)), significant weight loss ≥10% baseline body weight, low BMI, multiple medical co-
morbidities and poor general clinical condition. Due to limited resources, only patients who 
were being considered for curative treatment were staged with computed tomography (CT) 
scan of the chest, abdomen and pelvis. All patients who presented with DS grade 3 or 4 were 
referred to the Upper Gastroenterology surgical service for assessment for stent insertion. 
They were reviewed post stent insertion; an updated DS was assigned based on current 
clinical status and they were assessed for palliative RT. Palliative RT was offered to patients 
who had significant symptoms such as dysphagia and odynophagia and were in reasonable 
clinical condition. The aim was to maintain swallowing and for pain control, whereas patients 
whose general condition was too poor that palliative RT was thought not to add benefit were 
treated supportively.  
The choice of fractionation schedule was at the radiation oncologist’s discretion and three 
fractionation regimes were used at our centre; namely: 4.6 Gy x 4# (EQD2= 28.0Gy), 4.0Gy 
x 5# (EQD2= 28.0Gy) or 3.0Gy x 10# (EQD2=36.0Gy), assuming an / ratio of 3 for late 
effects. In general, the higher dose of RT was offered to patients who were PS (ECOG) 1-2.  
All patients were planned using a 2D simulation technique. The patients were positioned 
supine with head rest, knee and ankle stocks for immobilization and an anterior image was 
taken. In patients with a stent in situ, the field was placed to encompass the stent and an 
additional 2cm margin superiorly, inferiorly and laterally. In patients without a stent in situ, 
10ml of barium was given orally and a fluoroscopic image was taken to determine the site of 
the tumour, the field was then placed to encompass the lesion with an additional 5cm margin 
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superiorly and inferiorly and 2cm laterally. The patients were treated with photons, either Co-
60 or 6MV x-rays, once per day (Monday to Friday) with a treatment break on weekends. 
Patients were reassessed six weeks after completing RT and then routinely every three 
months or earlier if worsening dysphagia. The medical records of these patients were 
reviewed for objective worsening of DS at these visits. The DPFS was taken as the date from 
the completion of RT to worsening in DS by ≥1 point. Patients who died without returning to 
follow-up with complaint of increasing dysphagia were assumed to have dysphagia 
progression-free survival from time of radiation therapy until death. This information was 
used to calculate the median DPFS in the patient population and to compare the median 
DPFS in patients with and without stent insertions. The objective improvement in DS was 
calculated by determining the change in DS after RT for each patient. These values were used 
to determine the mean objective improvement in DS. The OS and post RT survival were 




Formal sample size calculations were not performed. The number of subjects was chosen based 
on feasibility of data collection and was considered sufficient to meet the study objectives. 
The data collected was stored in the REDCap (Research Electronic Data Capture) database and 
the interface was used to process the data and analyze the variables relevant to the study. The 
data collected using REDCap software was only accessible to the primary investigator and the 
student investigator.  
Stata MP version 14 software was used for data processing and analysis. Continuous variables 
were presented as mean/ standard deviation (SD) or median/interquartile range (IQR) 
depending on data distribution. Continuous data were analyzed using Independent t-test or 
Mann Whitney U test.  
Kaplan-Meier survival analysis was performed to determine the DFPS, OS and post-RT 
survival, and log-rank test was performed to test for significant differences in the probability 
of survival by stent insertion. Time 0 was defined as the day the patient completed RT. To 
determine the variables associated with DPFS, change in DS and post-RT survival, multiple 
linear regression analysis was performed. The variables analyzed were gender, age, 
PS(ECOG), DS at presentation, time of RT and post RT, histological subtype, site of primary 
tumour, RT fractionation schedule, stent insertion and weight loss >10% of baseline.  Variables 
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with p<0.20 in the univariate analysis (i.e., simple linear regression) were entered into the 
adjusted model. Model-building was then performed using a backward elimination technique 
and p values ≤0.05 were considered statistically significant. These results were displayed as 
charts and tables. 
 
Results 
A total of 84 patients presenting to the gastro-oesophageal carcinoma clinic between the period 
January 2015 and December 2016 met the inclusion criteria for the study. The patient and 
disease specific factors were grouped by variables such as gender, age group, PS (ECOG), 
histological subtype and location of primary tumour as tabulated in Table 1. 
Table 1: Demographics and disease related parameters in the study population. 
Gender Male Female 
No. of patients 46 (54.8%)  38 (45.2%) 
 
Age group (years) 18-24 25-30 31-40 41-50 51-60 61-70 71-80 >80 
No. of patients 0  0 3 16  30 19 13 3 
% of patients 0% 0% 3.6% 19.0% 35.7% 22.8% 15.5% 3.6% 
 
Performance Status (ECOG) 0 1 2 3 4 
No. of patients 0 (0%) 27 (32.1%) 33 (39.3%) 21 (25%) 3 (3.6%) 
 
Histological subtype Squamous cell carcinoma Adenocarcinoma  
No. of patients 78 (92.9%) 6 (7.1%) 
 
Location of primary 
tumour 
Upper 1/3 Middle 1/3 Lower 1/3 Gastro-oesophageal 
junction 
No. of patients 13 (15.5%) 46 (54.8%) 16 (22.6%) 6 (7.1%) 
 
Duration of symptoms <1mth >1-3mths >3-6mths 6-12mths 1-2y >2y 
 1 (1.2%) 22 (26.2%) 34 (40.5%) 20 (23.8%) 6 (7.1%) 1 (1.2%) 
 
Loss of weight  Yes No 
No. of patients 73 (86.9%) 11 (13.1%) 
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 <10% >10%  
 13 (17.8%) 60 (83.2%)  
There was a slight predominance of male patients 46 (54.8%) versus female patients 38 
(45.2%). The mean age was 59 years and modal age group was the 51-60. More than 50% of 
all patients were between 50 and 70 years. No patients in our study population were younger 
than 31 years of age. Most patients were observed to have a PS (ECOG) 2 or 3. Regarding 
duration of symptoms, most patients had symptoms for >3-6 months prior to presentation and 
the mean duration of symptoms was 6.1 months before seeking medical attention. The most 
common presenting symptoms were dysphagia and weight loss. More than 85% of patients had 
reported weight loss as shown in Table 1; of these >75% reported losing more than 10% of 
their baseline body weight. 
 
The most common histological subtype was squamous cell cancer (78 patients; 92.9%) versus 
adenocarcinoma (6 patients; 7.1%). The most common subsite among all patients was the 
middle third of the oesophagus (46 patients; 54.8%) followed by the lower third of the 
oesophagus (16 patients; 22.6%) The least common subsite was the gastro-oesophageal 
junction (6 patients; 7.1%). 
More than 90% of patients had a DS ≥2 at presentation. Approximately half of the patients had 
insertion of oesophageal stent (43 patients; 51.2%). Most patients presenting with DS ≤2 did 
not have oesophageal stent insertion. Of the patients with grade 4 dysphagia who were referred 
for stent insertion, one failed to have the procedure due to poor PS (ECOG). (Table 2). After 
stent insertion 100% of patients had an improvement in DS by ≥1 point. 
Table 2: Dysphagia score at presentation and in patients having stent insertion. 
   Stent insertion 
 Total Yes No  
Dysphagia Score    
0 2 (2.4%) 0  2  
1 5 (6.0%) 0 5 
2 40 (47.6%) 14 26 
3 22 (26.2%) 15 7 
4 15 (17.9%) 14 1 




For the delivery of palliative RT of the three fractionation regimens used, 18 (21%) of patients 
received 20.0Gy in 5#, 60 (71%) received 18.4Gy in 4# and 6 (7%) received 30.0Gy/10#. 
 
The DS, as assessed prior to starting RT, after RT and at time of progression of dysphagia 
were distributed, as shown in the figure 1. One patient was lost to follow-up and hence the 
data for the remaining 83 patients were analyzed. Prior to RT, the majority of patients (94%) 
had DS of grade 2 or grade 3. Our study did not include any patients with grade 4 dysphagia 
at time of RT as all patients seen post stent insertion with DS of grade 4 either did not meet 
the inclusion criteria or died prior to receiving RT. At the post RT review, 58 patients 
(68.9%) had DS of grade 2 or grade 3. One patient (1.2%) had a deterioration in DS to grade 
4 following RT. 
 
 
The duration of DPFS is represented in the column chart (Figure 2A) and scatter plot (Figure 
2B). The median DPFS calculated using the ungrouped data was 73 days [IQR: 35-145] (Figure 
2C). Simple and multiple linear regression analysis was performed to assess the association 
between DPFS and several variables. The median DPFS appeared to have a numerically 
significant difference between those with and without stent insertion with patients with a stent 
having a shorter duration of DPFS (median 54 days; [IQR: 31-98]) compared to those without 
a stent (median 83 days; [IQR: 45.5-176.5]) (Figure 2D). However, this result in conjunction 
0 1 2 3 4
Before RT 1.2% 4.8% 72.3% 21.7% 0.0%
After RT 12.0% 16.9% 60.2% 9.6% 1.2%



















Figure 1: Bar chart showing Dysphagia score at various time intervals
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with the log-rank test (p=0.224) confirmed that there was no statistical significance between 
DPFS in patients who were stented and those who were not. 
 
 
 A simple regression analysis showed the median duration of DPFS differed significantly by 
DS at presentation (p = 0.045), DS after RT (p <0.0001) and PS (ECOG) (p= 0.036) (Table 3). 
Using multiple linear regression, only the DS after RT (p <0.0001) was found to be 
significantly associated with DPFS. From this analysis, for every increase in DS by 1 point, the 
DPFS decreased by 61 days. 
 
Table 3: Simple linear regression analysis for variables associated with DPFS 
 
Simple linear regression analysis 
 
Beta coeff. 95% CI p value 
Stent insertion (Ref: No) -24.26 -70.65 - 22.13 0.301 
Age category (Ref: <60) -6.12 -52.77 - 40.54 0.795 
DS at presentation -24.94 -49.25 - -0.63 0.045* 
DS at time of RT -40.33 -82.56 - 1.89 0.061 
DS after RT -60.88 -85.05 - -36.71 <0.0001* 
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PS (Ref: PS 1/2) -53.66 -103.74 - -3.57 0.036* 
Gender (Ref: Female) -13.43 -60.17 - 33.31 0.569 
Histology (Ref: SCC) 42.43 -47.20 - 132.05 0.349 
Site of tumour (Ref: Upper 1/3)       
   Middle 1/3 -13.25 -81.53 - 55.03 0.700 
   Lower 1/3 28.36 -49.31 - 106.02 0.470 
   GEJ 54.08 -51.23 - 159.40 0.310 
RT fractionation sched (Ref: 20.0Gy/ 
5#)       
   18.4Gy in 4#  -32.94 -89.89 - 24.02 0.253 
   30Gy in 10# -58.44 -158.15 - 41.26 0.247 
Weight loss (Ref: No)       
   Yes, ≤10% 4.38 -85.58 - 94.3 0.923 
   Yes, >10% 8.88 -64.17 - 81.93 0.809 
 
The objective changes in DS when reassessed at six weeks after palliative RT were as follows: 
4 (4.8%) of patients had worsening of DS, 48 (57.8%) of patients had no change in DS from 
baseline, however, 31 patients (37.3%) had an improvement in DS following RT; 21 patients 
(25.3%) reported an improvement in DS by 1 point, 8 patients (9.6%) reported an improvement 
by 2 points and 2 patients (2.4%) reported an improvement by 3 points. The mean objective 
change in DS was 0.45 ± 0.89 points in all patients at six weeks post RT treatment and 0.28 ± 
0.80 points in stented and 0.63 ± 0.95 points in non-stented patients. Independent t test showed 
that the difference in mean objective change in DS between the stented and non-stented groups 
was not statistically significant (p=0.0757). 
 
Simple regression analysis showed DS at time of RT was the only variable significantly 
associated with mean objective change in DS (p = 0.001) (Table 4). Using multiple linear 
regression, only the DS at the time of RT (p = 0.001) was found to be significantly associated 
with DS. From this analysis, for every increase in DS at time of RT by 1 point, the mean 
objective change post RT decreased by 0.56 points. 
 
Table 4: Simple linear regression analysis for variables associated with mean objective 





Simple linear regression analysis 
  Beta coeff. 95% CI p value 
Stent insertion (Ref: No) -0.35 -0.73 - 0.04 0.076 
DS at presentation -0.03 -0.24 - 0.18 0.776 
DS at time of RT 0.56 0.22 - 0.90 0.001* 
PS (Ref: PS 1/2) -0.16 -0.59 - 0.27 0.465 
Histology (Ref: SCC) -0.12 -0.87 - 0.63 0.749 
Site of tumour (Ref: Upper 1/3) 
   
   Middle 1/3 -0.004 -0.58 - 0.58 0.990 
   Lower 1/3 0.16 -0.50 - 0.82 0.626 
   GEJ -0.08 -0.98 - 0.81 0.854 
RT fractionation sched (Ref: 20.0Gy/ 
5#)       
   18.4Gy in 4#  -0.17 -0.65 - 0.30 0.477 
   30Gy in 10# -0.61 -1.44 - 0.22 0.147 
Weight loss (Ref: No)       
   Yes, ≤10% 0.32 -0.43 - 1.06 0.404 
   Yes, >10% 0.13 -0.47 - 0.74 0.663 
 
The median OS of patients receiving RT was 150 days [IQR: 131 – 169]. The median OS in 
the RT patients without stents was 154 days [IQR: 99 – 211] while the median OS in the RT 
patients with stents was 136 days [IQR: 71 – 206]. The difference between these values 
compared by Mann Whitney U test was not statistically significant (p=0.387).  
 
The median survival following RT in the study population was 95 days [IQR: 41-154]. In the 
stented group of patients, the median survival was 81 days [IQR: 30-135] compared to 123 
days [IQR: 58-181] in the non-stented group of patients. The Mann Whitney U test was used 
to assess the correlation between post RT OS and stent insertion and showed that median 
survival post RT was significantly shorter in patients who had a stent insertion (p= 0.0482). 
 
Simple regression analysis showed the only variables which significantly affected post RT OS 
were DS at presentation (p = 0.027), change in DS post RT (p = 0.006) and PS (ECOG) (p = 
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0.031) (Table 5). Using multiple linear regression, DS at presentation (p = 0.002) and change 
in DS post RT (p <0.0001) were found to be significantly associated with post RT OS. From 
this analysis, for every 1 unit increase in DS at time of RT, duration of post-RT survival 
decreases by 75 days, holding other variables constant and for every 1 unit increase in the 
change in DS, duration of post-RT survival increases by 56 days, holding other variables 
constant. 
 
Table 5: Simple linear regression analysis for variables associated with post RT survival 
  Simple linear regression analysis 
  Beta coeff. 95% CI p value 
Age category (Ref: <60) -5.04 -57.67 - 47.60 0.849 
DS at presentation -30.52 -57.54 - -3.49 0.027* 
DS at time of RT -43.85 -90.97 - 3.27 0.068 
Change in DS 39.73 11.49 - 67.97 0.006* 
PS (Ref: PS 1/2) -61.65 -117.67 - -5.69 0.031* 
Gender (Ref: Female) -13.35 -66.10 - 39.41 0.616 
Histology (Ref: SCC) 41.86 -67.11 - 150.83 0.447 
Site of tumour (Ref: Upper 1/3)       
   Middle 1/3 -3.64 -79.86 - 72.57 0.924 
   Lower 1/3 38.94 -48.48 - 126.38 0.378 
   GEJ 76 -41.29 - 193.29 0.201 
RT fractionation sched (Ref: 20.0Gy/ 
5#)       
   18.4Gy in 4#  -30.11 -95.45 - 35.23 0.362 
   30Gy in 10# -44.26 -156.77 - 68.24 0.436 
Weight loss (Ref: No)       
   Yes, ≤10% 46.73 -55.96 - 149.43 0.368 
   Yes, >10% 12.79 -71.97 - 97.54 0.765 
 
Discussion 
From our study, the median DPFS after palliative RT was 73 days; the median DPFS in 
patients without stent insertion was approximately one month longer than the stented 
subgroup of patients (83 days vs 54 days), however this result was not statistically significant 
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between the two groups (p=0.224). Patients having DS 1 or 2 at presentation or post RT or PS 
(ECOG) ≤2 had significantly better DPFS. No other variables were associated with DPFS.  
Due to the assumption that patients who died were considered to have progression of 
dysphagia at the time of death, the estimated value for median DPFS in our study represents 
the worst case scenario and is most likely to represent a minimum value as the cause of death 
may not be directly related to failure to swallow in these patients. 
 
Following palliative RT, the median change in DS was 0 with most patients (57.8%) 
remaining unchanged following treatment. The mean objective change in DS was calculated 
as 0.45 ± 0.89 points. This value is much lower than described in studies examining the 
impact of stent insertion as the sole intervention(5) which suggests that patients receiving RT 
have a less dramatic improvement in dysphagia than patients who have stent insertion. 
Existing literature reports approximately 60-70% of patients have improvement in DS 
immediately following stent insertion(14, 21, 22). The relief of dysphagia following RT is slower 
usually taking approximately 4-6 weeks post RT to improve(11, 23).  From our data, at six 
weeks post RT only 37.5% of patients reported improvement in DS thus supporting previous 
data that stenting provides a more rapid relief of dysphagia than RT.  
 
In our study population, the median OS was 150 days, the median OS in the RT patients 
without stents was 154 days while the median OS in the RT patients with stents was 136 
days. Previous data has suggested the median OS in patients with only covered stent insertion 
to be 62 days (10). Thus, our data suggests that the RT with or without stenting leads to an 
improved median OS. 
 
The median post RT survival in the study population was 95 days. The post RT survival was 
significantly longer in the non-stented group than in the stented group of patients (123 versus 
81 days p= 0.0482).  PS (ECOG ≤2) and DS ≤ 2 at presentation and after RT were 
significantly associated with improved median post RT survival on simple linear regression 
analysis. Using the DPFS curve for all patients who received radiation, at the time of 95 days 
(median post RT survival), 40% of patients still did not have any progression of dysphagia. 
This validates the use of RT as an effective method of palliation of dysphagia to ensure that 




Most patients who had stents inserted had worse DS at presentation which can be attributed 
to more advanced disease and possibly more aggressive tumour biology. Cumulatively, these 
factors could lead to decreased tumour response and control following palliative RT and 
hence account for the poorer response in all measured outcomes in the stented subgroup of 
patients in our study population. Other than DS and PS (ECOG), no other patient or tumour 
factors significantly affected the outcomes in our patients treated with palliative RT. As such, 
PS and DS at presentation can be used to guide patient selection for those who will benefit 
the most from palliative RT, which can be useful in the setting of limited resources. 
Additionally, the DS and mean objective change in DS after RT can also be used to 
determine which patients are likely to have a longer survival and hence may benefit from 
further palliative therapies. 
 
A major problem in developing countries such as our setting, revolves around access to care 
and health education resulting in a high proportion of patients presenting late with advanced 
stage disease(24).  In our study, approximately 75% of patients reported having symptoms for 
more than 3 months and almost 10% of patients had symptoms for more than a year. 
Approximately 70% of patients presented with PS (ECOG) ≥ 2 and more than 80% of 
patients presented with significant weight loss of more than 10% baseline body weight.  This 
can be attributed to the advanced DS at presentation with more than 90% of patients having a 
DS at least grade 2. This affects nutritional status, PS (ECOG) and contributes to the poor 
general physical condition that precludes many oesophageal cancer patients from receiving 
radical treatment(6, 7).  
When examining patient and disease characteristics, a male predominance is seen in our 
study (54.8%) with a higher incidence of squamous cell cancer (92.9%) and the 
predominance of tumours of the upper and middle oesophagus (70.3%). Previous data reports 
oesophageal cancers located in the upper oesophagus are primarily squamous cell cancers and 
are associated with lifestyle and cultural factors such as diet, smoking and heavy alcohol 
consumption(25) and generally tend to be more prevalent in lower socio-economic 
populations(2). These factors are also noted in a large proportion of our study population. 
 
At our centre, the standard fractionation schedule used is 18.4Gy in 4 fractions which has the 
same EQD2 as 20Gy in 5 fractions, a frequently used palliative fractionation schedule(26). 
Notably, the fractionation schedule did not impact the objective response to RT. This is of 
significance in low- and middle-income countries where resources are scarce as a shorter 
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fractionation schedule (ie. 18.4 Gy in 4 fractions) can improve workflow. The acute toxicity 
and complication associated with this regimen from our experience is tolerable, however was 
not described in the study and hence further research is necessary to for comparison in this 
regard to other fractionation schedules. 
 
A limitation of our study was that the impact of RT on the other symptoms associated with 
locally advanced oesophageal cancer such as odynophagia, pain and regurgitation was not 
assessed. Existing data suggests benefit of radiation for palliation of these symptoms but the 
duration of response is unknown(27). In addition, there was an objective assessment of the DS 
following RT, however, the impact on nutritional status and weight gain was not assessed. 




RT is beneficial in the palliation of dysphagia associated with locally advanced and 
metastatic squamous cell cancer of the oesophagus with respect to DPFS and improvement in 
DS. The median duration of DPFS following RT was 73 days; in relation to the post RT 
survival, this was effective in palliating dysphagia in approximately 60% of patients until 
time of death. Patients who have stent insertions had a shorter duration of response compared 
to patients without stent insertions. In the setting of patients with locally advanced and 
metastatic oesophageal cancer who are receiving palliative treatment, PS (ECOG) and DS at 
presentation can be used as a surrogate to determine which patients will benefit the most from 
RT. A short course of RT can be an effective method of palliation in these patients in a 
limited resource setting. Additional investigations on quality of life and impact of RT on 
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Table 1: DYSPHAGIA SCORE GRADING SYSTEM (Knyrim et al; 1993) 
Grade 0 Able to eat all solids/ No dysphagia 
Grade 1 Able to eat only some solid foods 
Grade 2 Able to eat only soft foods 
Grade 3 Able to drink liquids only 
Grade 4 Complete dysphagia 
 
 
Table 2: LIST OF ABBREVIATIONS 
Abbreviation Meaning 
2D Two-dimensional 
BMI Body mass Index 
Co-60 Cobalt-60 
DPFS Dysphagia progression-free survival 
DS Dysphgia score 
EBRT External beam radiation therapy 
ECOG Eastern Cooperative Oncology Group 
EQD2 Equivalent dose in 2Gy fractions 
GEJ Gastro-oesophageal junction 
IQR Interquartile range 
MV Megavoltage 
OS Overall survival 
PS Performance Status 
REDCap Research Electronic Data Capture 
RT Radiation therapy 
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